End-to-End Prediction of Subcutaneous Peptide Absorption Rates from Amino Acid Sequences Using Physics-Informed Machine Learning
- 3 November 2026
- journal article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
Abstract
The subcutaneous (SC) absorption rate constant (ka) dictates critical pharmacokinetic and dosing parameters of injectable peptide therapeutics, yet currently, it cannot be predicted prior to clinical testing, forcing empirical decisions at the discovery and formulation stages. We address this important gap by constructing the first end-to-end machine learning framework that predicts SC ka, both point predictions and prediction intervals, purely from the amino acid sequence and conjugate chemistry. For developing the model, we first curated a comprehensive database of 41 human clinical ka values (0.0077−7.61 h−1), covering unmodified, fatty-acid-acylated, and protein-conjugated peptides. These data were subsequently encoded into a combination of protein language model (ESM-2) embeddings, chemical language model (ChemBERTa) embeddings, and 30 physics-informed molecular descriptors designed to capture the physical variables governing SC transport. Seven machine learning (ML) architectures and ensembles thereof were trained, with the best model (NGBoost) achieving R2 = 0.850 under leave-one-out cross-validation, a markedly high accuracy given the large variance in the clinically reported ka values. Notably, models trained on the physics-informed molecular descriptors or combinations thereof substantially outperformed models trained purely on learned embeddings (ESM-2, ChemBERTa)a direct consequence of the small scale of our training dataset. SHAP interpretability analysis indicates that predictions are consistent with established SC absorption physics, with properties including molecular weight, net charge, hydrophobicity, and acyl chain molecular characteristics dictating model predictions. Leveraging Jackknife+, the developed framework also reports ka prediction uncertainties (prediction intervals). Overall, this framework enables high-throughput sequence-level candidate ranking before in vivo data become available, supporting the rational early-stage development of peptide therapeutics.Keywords
This publication has 40 references indexed in Scilit:
- Focus on therapeutic peptides and their deliveryInternational Journal of Pharmaceutics, 2025
- Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatideCPT: Pharmacometrics & Systems Pharmacology, 2024
- Characterization and impact of peptide physicochemical properties on oral and subcutaneous deliveryAdvanced Drug Delivery Reviews, 2022
- Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approachesAdvanced Drug Delivery Reviews, 2020
- Population Pharmacokinetics of Semaglutide for Type 2 DiabetesDiabetes Therapy, 2019
- Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing’s Disease PatientsClinical Pharmacokinetics, 2017
- Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical speciesEuropean Journal of Pharmaceutical Sciences, 2017
- Modeling Pharmacokinetic Profiles of Insulin Regimens to Enhance Understanding of Subcutaneous Insulin RegimensThe Journal of Clinical Pharmacology, 2017
- Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical TrialsClinical Pharmacokinetics, 2015
- Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make BiobettersBioDrugs, 2015